

Pierre-Jean Lamy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5148169/publications.pdf>

Version: 2024-02-01

82
papers

3,017
citations

147801

31
h-index

175258

52
g-index

108
all docs

108
docs citations

108
times ranked

5667
citing authors

#	ARTICLE	IF	CITATIONS
1	Occupation and prostate Cancer risk: results from the epidemiological study of prostate cancer (EPICAP). Journal of Occupational Medicine and Toxicology, 2022, 17, 5.	2.2	4
2	Androgenic hormones and the excess male mortality observed in COVID-19 patients: new convergent data. World Journal of Urology, 2021, 39, 3121-3123.	2.2	15
3	Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. European Journal of Cancer, 2021, 146, 30-47.	2.8	81
4	Mass Spectrometry as a Highly Sensitive Method for Specific Circulating Tumor DNA Analysis in NSCLC: A Comparison Study. Cancers, 2020, 12, 3002.	3.7	22
5	Circadian genes polymorphisms, night work and prostate cancer risk: Findings from the EPICAP study. International Journal of Cancer, 2020, 147, 3119-3129.	5.1	16
6	Body mass index trajectories and prostate cancer risk: Results from the EPICAP study. Cancer Medicine, 2020, 9, 6421-6429.	2.8	19
7	BRCA1 Promoter Hypermethylation is Associated with Good Prognosis and Chemosensitivity in Triple-Negative Breast Cancer. Cancers, 2020, 12, 828.	3.7	27
8	Abstract P3-08-25: Simosein registry, the French national real-life prospective evaluation of the impact of EndopredictA® (EPclin) on treatment decision in ER-positive, HER2-negative breast cancers. , 2020, , .		0
9	PIK3CA mutations early persistence in cell-free tumor DNA as a negative prognostic factor in metastatic breast cancer patients treated with hormonal therapy. Breast Cancer Research and Treatment, 2019, 177, 659-667.	2.5	17
10	Circadian genes and risk of prostate cancer: Findings from the EPICAP study. International Journal of Cancer, 2019, 145, 1745-1753.	5.1	17
11	Quantification of uPA in breast tumour tissue extracts by microarray immunoassay: Comparison with ELISA technology. Journal of Applied Biomedicine, 2018, 16, 214-220.	1.7	0
12	Serum Vitamin D Levels Affect Pathologic Complete Response in Patients Undergoing Neoadjuvant Systemic Therapy for Operable Breast Cancer. Clinical Breast Cancer, 2018, 18, 144-149.	2.4	10
13	Prostatitis, other genitourinary infections and prostate cancer risk: Influence of non-steroidal anti-inflammatory drugs? Results from the EPICAP study. International Journal of Cancer, 2018, 143, 1644-1651.	5.1	11
14	Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. European Urology Focus, 2018, 4, 790-803.	3.1	64
15	Relevance of total PSA and free PSA prescriptions. Annales De Biologie Clinique, 2018, 76, 659-663.	0.1	1
16	Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes. Scientific Reports, 2018, 8, 15931.	3.3	67
17	Night work and prostate cancer risk: results from the EPICAP Study. Occupational and Environmental Medicine, 2018, 75, 573-581.	2.8	39
18	Impact of vitamin D on pathological complete response and survival following neoadjuvant chemotherapy for breast cancer: a retrospective study. BMC Cancer, 2018, 18, 770.	2.6	15

#	ARTICLE	IF	CITATIONS
19	Prognostic value of androgen receptor and FOXA1 co-expression in non-metastatic triple negative breast cancer and correlation with other biomarkers. <i>British Journal of Cancer</i> , 2018, 119, 76-79.	6.4	48
20	Family history of breast cancer increases the risk of prostate cancer: results from the EPICAP study. <i>Oncotarget</i> , 2018, 9, 23661-23669.	1.8	8
21	Abdominal obesity and prostate cancer risk: epidemiological evidence from the EPICAP study. <i>Oncotarget</i> , 2018, 9, 34485-34494.	1.8	33
22	First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma. <i>Anticancer Research</i> , 2018, 38, 2909-2914.	1.1	3
23	Added value of hepcidin quantification for the diagnosis and follow-up of anemia-related diseases. <i>Annales De Biologie Clinique</i> , 2017, 75, 9-18.	0.1	3
24	Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery. <i>Annales D'Endocrinologie</i> , 2017, 78, 162-175.	1.4	39
25	Nonsteroidal anti-inflammatory drugs (NSAIDs) and prostate cancer risk: results from the EPICAP study. <i>Cancer Medicine</i> , 2017, 6, 2461-2470.	2.8	48
26	Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2 ⁺ pN0 early breast cancers. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 611-621.	2.5	11
27	Kinetics of HE4 and CA125 markers in metastatic ovarian cancer: The META4 study.. <i>Journal of Clinical Oncology</i> , 2017, 35, e17059-e17059.	1.6	2
28	High fasting serum insulin level due to autoantibody interference in insulin immunoassay discloses autoimmune insulin syndrome: a case report. <i>Annales De Biologie Clinique</i> , 2016, 74, 490-494.	0.1	4
29	Serum HER2 extra-cellular domain, S100 β and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients. <i>BMC Cancer</i> , 2016, 16, 428.	2.6	26
30	Serum NSE, MMP β 9 and HER2 extracellular domain are associated with brain metastases in metastatic breast cancer patients: predictive biomarkers for brain metastases?. <i>International Journal of Cancer</i> , 2016, 139, 2299-2311.	5.1	23
31	Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study. <i>Annals of Oncology</i> , 2016, 27, 1235-1241.	1.2	25
32	High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers. <i>BMC Cancer</i> , 2015, 15, 986.	2.6	19
33	Randomized phase II/III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial. <i>Annals of Oncology</i> , 2015, 26, 908-914.	1.2	81
34	Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?. <i>Future Oncology</i> , 2015, 11, 557-559.	2.4	15
35	Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 366-373.	2.8	34
36	Serum HE4: An Independent Prognostic Factor in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2015, 10, e0128836.	2.5	28

#	ARTICLE	IF	CITATIONS
37	Abstract P5-21-02: Final results of the VitaCal randomized phase III study evaluating the impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients. , 2015, , .		0
38	Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer. Clinical and Translational Medicine, 2014, 3, 31.	4.0	10
39	Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer. Future Oncology, 2014, 10, 195-209.	2.4	15
40	Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nature Medicine, 2014, 20, 430-435.	30.7	582
41	Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. BMC Cancer, 2014, 14, 106.	2.6	20
42	Iron homeostasis and anemia markers in early breast cancer. Clinica Chimica Acta, 2014, 434, 34-40.	1.1	42
43	Cancer de la prostate: les niveaux de preuve des biomarqueurs de la détection précoce. Medecine Nucleaire, 2014, 38, 14-17.	0.2	0
44	Comparison of prostate health index and PCA3 values in patients with clinical or biologic suspicion of prostate cancer.. Journal of Clinical Oncology, 2014, 32, 5055-5055.	1.6	0
45	Anemia and iron biomarkers in patients with early breast cancer. Diagnostic value of hepcidin and 1833-41.	2.3	14
46	Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. BMC Cancer, 2013, 13, 472.	2.6	11
47	SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC Cancer, 2013, 13, 351.	2.6	52
48	BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer. BMC Cancer, 2013, 13, 523.	2.6	44
49	Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load. Translational Oncology, 2013, 6, 319-IN8.	3.7	143
50	The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond. Biochimica Et Biophysica Acta: Reviews on Cancer, 2013, 1836, 146-157.	7.4	34
51	Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers. International Journal of Cancer, 2013, 132, 1105-1113.	5.1	41
52	Re: Clinical Validity/Utility, Change in Practice Patterns, and Economic Implications of Risk Stratifiers to Predict Outcomes for Early-Stage Breast Cancer: A Systematic Review. Journal of the National Cancer Institute, 2013, 105, 149-149.	6.3	1
53	Cathepsin D stimulates the activities of secreted plasminogen activators in the breast cancer acidic environment. International Journal of Oncology, 2013, 43, 1683-1690.	3.3	22
54	KRAS genotyping in rectal adenocarcinoma specimens with low tumor cellularity after neoadjuvant treatment. Modern Pathology, 2012, 25, 731-739.	5.5	33

#	ARTICLE	IF	CITATIONS
55	<i>TOP2A</i> Amplification in Breast Cancer in the Absence of That of <i>HER-2</i>: Myth or Reality?. <i>Oncologist</i> , 2012, 17, e60-e61.	3.7	2
56	Serum Autoantibody Signature of Ductal Carcinoma <i>In Situ</i> Progression to Invasive Breast Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 1992-2000.	7.0	36
57	HER2 shedding and serum HER2 extracellular domain: Biology and clinical utility in breast cancer. <i>Cancer Treatment Reviews</i> , 2012, 38, 133-142.	7.7	109
58	Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 120-127.	2.2	3
59	Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 709-717.	2.5	38
60	Worldwide variations in EGFR somatic mutations: a challenge for personalized medicine. <i>Diagnostic Pathology</i> , 2012, 7, 13.	2.0	13
61	Abstract 679: Retrospective evaluation of the BRCA1 - PARP pathway in breast cancer tissues. , 2012, , .		0
62	Quantification and clinical relevance of gene amplification at chromosome 17q12-q21 in human epidermal growth factor receptor 2-amplified breast cancers. <i>Breast Cancer Research</i> , 2011, 13, R15.	5.0	56
63	Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles. <i>Breast Cancer Research</i> , 2011, 13, R133.	5.0	37
64	KRAS Mutation Detection in Paired Frozen and Formalin-Fixed Paraffin-Embedded (FFPE) Colorectal Cancer Tissues. <i>International Journal of Molecular Sciences</i> , 2011, 12, 3191-3204.	4.1	52
65	Serum protein signature may improve detection of ductal carcinoma in situ of the breast. <i>Oncogene</i> , 2010, 29, 550-560.	5.9	24
66	KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?. <i>British Journal of Cancer</i> , 2010, 102, 1074-1075.	6.4	6
67	Classification moléculaire des cancers du sein: utilité en clinique. <i>Medecine Nucleaire</i> , 2010, 34, 32-43.	0.2	1
68	Impact de la TEP/TDM au 18F-FDG dans la prise en charge des patients atteints de cancer thyroïdien différentiel. <i>Medecine Nucleaire</i> , 2010, 34, 78-87.	0.2	2
69	Clinical Utility of Serum Human Epidermal Growth Factor Receptor 2 Extracellular Domain Levels: Stop the Shilly-Shally" It Is Time for a Well-Designed, Large-Scale Prospective Study. <i>Journal of Clinical Oncology</i> , 2009, 27, e286-e287.	1.6	10
70	Identification of a New Panel of Serum Autoantibodies Associated with the Presence of <i>In situ</i> Carcinoma of the Breast in Younger Women. <i>Clinical Cancer Research</i> , 2009, 15, 4733-4741.	7.0	99
71	SERUM PRO-MATRIX METALLOPROTEINASE-7 (PRO-MMP-7) AS A PREDICTIVE MARKER FOR EARLY PROGRESSION AFTER NEPHRECTOMY IN RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2009, 181, 109-109.	0.4	0
72	Identification of Pro-MMP-7 as a Serum Marker for Renal Cell Carcinoma by Use of Proteomic Analysis. <i>Clinical Chemistry</i> , 2008, 54, 574-581.	3.2	50

#	ARTICLE	IF	CITATIONS
73	Circulating Serum Vascular Endothelial Growth Factor is Not a Prognostic Factor of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1119-1126.	1.1	23
74	Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor Type-1 mRNA Assessment in Breast Cancer by Means of NASBA. <i>American Journal of Clinical Pathology</i> , 2007, 128, 404-413.	0.7	16
75	Docetaxel and Cisplatin in Patients With Metastatic Androgen Independent Prostate Cancer and Circulating Neuroendocrine Markers. <i>Journal of Urology</i> , 2007, 178, 844-848.	0.4	81
76	NASBA: a novel approach to assess hormonal receptors and ERBB2 status in breast cancer. <i>Clinical Chemistry and Laboratory Medicine</i> , 2006, 44, 3-12.	2.3	22
77	Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer. <i>British Journal of Cancer</i> , 2004, 91, 430-433.	6.4	19
78	Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. <i>Lung Cancer</i> , 2003, 39, 131-138.	2.0	84
79	Progesterone Receptor Quantification as a Strong Prognostic Determinant in Postmenopausal Breast Cancer Women under Tamoxifen Therapy. <i>Breast Cancer Research and Treatment</i> , 2002, 76, 65-71.	2.5	49
80	Analysis of the potential contribution of estrogen receptor (ER) ? in ER cytosolic assay of breast cancer. <i>International Journal of Cancer</i> , 2001, 95, 205-208.	5.1	19
81	Measles Virus Exploits Dendritic Cells to Suppress CD4+ T-Cell Proliferation via Expression of Surface Viral Glycoproteins Independently of T-Cell Trans-infection. <i>Cellular Immunology</i> , 2001, 214, 173-183.	3.0	49
82	Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer. <i>Lung Cancer</i> , 2000, 29, 197-203.	2.0	88